Human Forms and Body Parts Trigger Strong Reactions in the Brain
Partnership aims to set new industry standards for managing mental health and cognitive conditions
SINTX TECHNOLOGIES SECURES PATENT ALLOWANCE FOR WIDE-RANGING SILICON NITRIDE BIOMATERIAL APPLICATIONS
BD has reached an agreement with the U.S. SEC to resolve the previously disclosed investigation related to prior public disclosures.
Recursion reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors.
With limited options available to treat Pancreatic Ductal Adenocarcinoma (PDAC), the Company’s Universal Cancer Treatment Platform may provide hope for patients and doctors
BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance
Prolaris, MyRisk, and Precise Tumor Testing Validated Across Cancer Stages, Elevating Company’s Comprehensive Patient-Centric Solutions
Presentations include analytical validation of Myriad’s high-definition tumor informed MRD assay for breast cancer and its Breast Cancer Risk Assessment Tool MyRisk® with RiskScore®
Canary Speech recognized for achievements in non-invasive diagnostics in the most promising private digital health companies across the globe.
First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesized
Embolic device designed for improved preparation, delivery, and deep vessel filling for treating tumors and other interventional oncology uses.